By 10:53 a.m., the Sensex had dumped 551 points at 25,214 and the Nifty slipped 171 points at 7,649.
The broader markets are trading dismal in line with the benchmark indices- BSE Midcapa nd Smallcap indices are down almsot 1%. Market breadth remain weak with 947 losers and 316 gainers on the BSE.
Also Read
Back home, foreign portfolio investors (FPIs) sold shares worth a net Rs 394.31 crore yesterday as per provisional data released by the stock exchanges. Domestic institutional investors (DIIs) bought shares worth a net Rs 840.35 crore yesterday as per provisional data.
GLOBAL MARKETS
Asian shares were mixed on Friday as caution about a US jobs report jostled with signals from the European Central Bank that it is willing to take further steps to shore up the European economy.
MSCI's broadest index of Asia-Pacific shares outside Japan slipped 0.2% after rising in early trade. They've fallen 3.4% this week. Japan's Nikkei fell 0.9%, extending losses this week to 6.0%.
Wall Street shares ended up on Thursday, though they pared back much of earlier gains. The S&P 500 gained 0.1% but the Nasdaq Composite ended 0.4% lower.
SECTORS & STOCKS
BSE Bankex has plunged by over 1.5% followed by counters like Auto, Metal Power and Realty, all slipping over 1% each. Infact, all the sectoral indices are trading in negative zone.
The top losers from the Sensex pack are Tata Steel, Axis Bank, Tata Motors, BHEL, Hero Moto, Vedanta, HDFC Bank and HDFC.
According to the CRISIL report, the proposed regime for computing base rate, the benchmark for pricing loans, might burn a big hole in the bottom line of banks in the next financial year. Banks might take a one-time hit of Rs 20,000 crore to follow the Reserve Bank of India (RBI)’s prescription to use marginal cost of funding to decide base rate.
London based diversified metals and mining major Vedanta Resources today ruled out any rethink on its planned shutdown of the Lanjigarh refinery in Odisha.
On the gaining side, Cipla is in talks to acquire Hetero Drugs' US business, a media report said on Thursday. The deal values the US business at $500-550 million and will give Cipla access to generic drug portfolio and abbreviated new drug application pipeline, the report said. Shares of Cipla are up by almost 2%.
Wipro has gained marginally after bagging contract to become a digital partner of a, European football team.
Lupin has gained over 0.5% after launching 40 mg variant of Duloxetine delayed-release capsule in the US market.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)